BrueraE, SweeneyC: Methadone use in cancer patients with pain: A review. J Palliat Med, 2002; 5:127–138.
2.
FisherK, StilesC, HagenNA: Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: A pilot study. J Pain Symptom Manage, 2004; 28:619–625.
3.
ViganoA, FanD, BrueraE: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain, 1996; 67:115–119.
4.
AnglhelscuDL, FaughnanLG, HankinsGM, et al.: Methadone use in children and young adults at a cancer center: A retrospective study. J Opioid Manag, 2011; 7:353–361.
5.
FifeA, PosteierA, FloodA, et al.: Methadone conversion in infants and children: Retrospective cohort study of 199 pediatric inpatients. J Opioid Manag, 2016; 12:123–130.
6.
KornickCA, KilbornMJ, Santiago-Palma, et al.: QTc interval prolongation associated with intravenous methadone. Pain, 2003; 105:499–506.
7.
FitzgibbonDR, ReadyLB: Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain, 1997; 73:259–261.
8.
Santiago-PalmaJ, KhojainovaN, KornickC, et al.: Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer, 2001; 92:1919–1925.
RipamontiC, ZeccaE, BrunelliC, et al.: Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol, 1995; 6:841–843.
11.
WantaanabeS, BelzileM, KuehnN, et al.: Capsules and suppositories of methadone for patients cancer pain: Clinical and economic considerations. Cancer Treat Rev, 1996; 22:131–136.
